Newsletter Issue 1

Sandor Lifesciences Pvt Ltd
Sandor Lifesciences Pvt LtdNABL ACCREDITED MEDICAL GENETICS LABORATORY à Sandor Lifescience

Dear Clinicians, We are happy to launch our first edition of quarterly newsletter bringing to your exotic clinical cases with unusual symptoms and/or diagnostic findings, or cases involving rare diseases. We will also share with you our recent achievements, the future roadmap and new test launches in the field of rare disorder diagnosis. We hope that you will find this information quite valuable as it may assist you to derive even better patient management. Thanks for reading! Team Sandor

Issue 1, December 2015
Sandor Lifesciences Pvt. Ltd. 8-2-326/5, Plot No. 1, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: U85110TG2004PTC043672
Page 1
New Tests Now Available
1. Newborn Screening
2. Vitamins
3. Lactate & Pyruvate
4. Pterins
Tests Coming Soon
1. LSD’s screening
2. Non-invasive prenatal testing (NIPT)
Dear Clinicians,
We are happy to launch our first edition of quarterly
newsletter bringing to your exotic clinical cases with
unusual symptoms and/or diagnostic findings, or
cases involving rare diseases. We will also share with
you our recent achievements, the future roadmap
and new test launches in the field of rare disorder
diagnosis. We hope that you will find this information
quite valuable as it may assist you to derive even
better patient management.
Thanks for reading!
Team Sandor
In This Issue
1. Wolman Disease
2. Lysinuric Protein Intolerance (LPI)
3. Molecular Diagnostics of Infectious Disease
Consultant Geneticist & Lab Chief
Dr. Jayanthi Undamatla
jayanthi@sandor.co.in, +91 83310 11704
Consultant Biochemist
Dr. Maheshwar Reddy
mahesh@sandor.co.in, +91 83319 30016
Principal Scientist Flow Cytometry
Dr. Nagesh Narayan Pandey
nagesh@sandor.co.in, +91 83329 59992
Consultant Molecular Diagnostics
Dr. Raghuram
raghu@sandor.co.in, +91 94406 97547
Issue 1, December 2015
Sandor Lifesciences Pvt. Ltd. 8-2-326/5, Plot No. 1, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: U85110TG2004PTC043672
Page 2
Case 1: Wolman disease (OMIM No: 278000)
A two months male child with acid lipase enzyme activity deficiency
Clinical presentation: The child presented with clinical suspicion of Wolman disease with hepatosplenomegaly,
calcified adrenal glands, diarrhea and failure to thrive.
Laboratory work up: Acid lipase enzyme activity was found to be deficient (~ 2.1% of mean normal) in leukocytes.
In view of the age of onset and clinical presentation the diagnosis was consistent with Wolman disease.
About the disorder: Both Wolman disease and Cholesteryl ester storage disease are rare autosomal recessive
lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase, the differentiating factor being
the age of onset and clinical presentation. Wolman disease is the early onset form and develops during the first
few weeks or month of life and presents with hepatomegaly, liver disease, adrenal gland calcification, vomiting,
diarrhea, and failure to thrive. The late onset form which is known as Cholesteryl ester storage disease (CESD)
typically presents later in childhood or even adulthood and presents with hepatosplenomegaly, coronary artery
disease, stroke, altered liver function, jaundice, steatosis, fibrosis, cirrhosis and related complications of
esophageal varices, and/or liver failure, anemia and/or thrombocytopenia. Residual enzyme activity of ≤5% of
mean normal is obtained in Wolman disease and 2% - 11% of mean normal is observed in Cholesterol ester storage
disease (CESD).
Prevalence: Wolman disease is estimated to occur in 1 in 100,000 newborns and CESD is 1 in 1, 30,000 live births.
Differentials: Owing to its similarity with other cardiovascular, liver and metabolic diseases, the differential
diagnosis of these disorders can be challenging. The differential diagnosis includes:
Niemann-Pick disease, Types A/B
Gaucher disease
Familial hypercholesterolemia
Chanarin dorfman syndrome
Copyrights:
http://ommbid.mhmedical.com/data/Books/ommbid/ch142fg2.jpg
http://pmj.bmj.com/content/78/923/567/F2.large.jpg
Issue 1, December 2015
Sandor Lifesciences Pvt. Ltd. 8-2-326/5, Plot No. 1, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: U85110TG2004PTC043672
Page 3
Case 2: Lysinuric Protein Intolerance (LPI) (OMIM No: 222700)
A two years eleven months male child born from a consanguineous marriage presented with hyper ammonia
Clinical presentation: The child presented with an eight month history of daily episodic irritability lasting for up to
twelve hours associated slow congitive regression. The child was being treated for epilepsy with multiple
anticonvulsants without any improvement. His EEG was normal and MRI had shown symmetrical periventricular T2
hyperintensities. On clinical Examination he was pale, ataxic and had mild hepatosplenomegaly.
Prior work up: His serum Ammonia was significantly raised at 840 micromol/l as were plasma ferritin with mild
derangment of liver function. Clinically urea cycle disorder was suspected.
Diagnostic workup: The patient was referred for metabolic work up including urine organic acid analysis, urine &
plasma amino acid analysis. Urine organic acid analysis revealed a 689-fold elevation of orotic acid and 6-fold
elevation of uracil. Plasma amino acid analysis revealed an elevation of alanine, low level of lysine, absence of
ornithine but arginine was within normal limits. Urine amino acid analysis revealed increase in multiple amino acids
including glutamic acid, glutamine, α-amino adipic acid, citrulline, amino butyric acid, cystine, methionine,
phenylalanine, lysine, and arginine, but ornithine was within normal limits.
Treatment: The child showed dramatic improvement in his symptomatology after starting anitscavanging therapy
(Sodium benzoate and Citrulline) and protein restricted diet.
About the disorder: Lysinuric protein intolerance is an autosomal recessive disorder caused by defective cationic
amino acid (CAA) transport at the basolateral membrane of epithelial cells in kidney and intestine. Clinical
symptoms are presented at infancy after weaning from being breast-fed and include hepatomegaly, pancreatitis,
splenomegaly, nausea, vomiting diarrhea, and aversion to protein rich food, impaired intestinal absorption of
cationic amino acids, chronic renal disease, and impaired renal absorption of CAA, mental retardation, postprandial
hyperammonemia, anemia, leucopenia and thrombocytopenia. The patients look as if they have protein deficiency
or malnutrition, loose skin, hypotonia, muscle weakness, interstitial changes on chest x-ray, respiratory
insufficiency and pulmonary hemorrhage.
The phenotypic variability of lysinuric protein intolerance (LPI) has resulted in various differentials.
Differentials
Urea Cycle disorders
Malnutrition/ malabsorptive diseases
Lysosomal storage diseases (LSDs)
Hemophagocytic lymphohistiocytosis/macrophagic activation syndrome
Autoimmune disorders
Issue 1, December 2015
Sandor Lifesciences Pvt. Ltd. 8-2-326/5, Plot No. 1, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: U85110TG2004PTC043672
Page 4
Urine Amino acid Chromatogram
25.0 50.0 75.0 100.0 125.0 min
0
100
200
300
400
500
600
700
800
900
1000
mV
Detector A:Ex:350nm,Em:450nm
P-Ser
Tau
Asp
Thr
Ser
Asn
Glu
aAAA
Gly
Ala
Cit
aABA
Val
Cys
Met
Ile
Leu
Tyr
Phe
b-AlabAIBA
GABA
Trp
His1-Me-His
3-Me-His
Car
Ans
Orn
Lys
NH3+Ethanolamine
Arg
Urine Organic acid chromatogram
5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0
0.00
0.25
0.50
0.75
1.00
1.25
1.50
(x10,000,000)
TIC
Oxalicacid-2TMS
Malonicacid-2TMS
Succinicacid-2TMS
Uracil-2TMS
Tropicacid(IS)
2-Ketoglutaricacid-oxime-3TMS
Oroticacid-3TMS
Hippuricacid-TMS
Citricacid-4TMS
PalmiticacidTMS
Margaricacid-TMS(IS)
Tetracosane(IS)
Plasma Amino acid Chromatogram
25.0 50.0 75.0 100.0 125.0 min
0
100
200
300
400
500
600
700
800
900
1000
mV
Detector A:Ex:350nm,Em:450nm
P-Ser
Tau
Asp
Thr
Ser
Asn
Glu
Gly
Ala
Cit
aABA
Val
Cys
Met
Ile
Leu
Tyr
Phe
b-AlabAIBA
Trp
His1-Me-His
Lys
NH3+Ethanolamine
Arg
Issue 1, December 2015
Sandor Lifesciences Pvt. Ltd. 8-2-326/5, Plot No. 1, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: U85110TG2004PTC043672
Page 5
Molecular Diagnostics of Infectious Diseases (New Tests)
At Sandor, our goal is to assist clinicians to make quicker decisions in the prognosis and management of different
infections. Molecular identification in clinical settings is a faster method allowing clinicians to avoid prolonged
management based on empiric medication and to implement specific therapy.
Molecular diagnostics based on Nucleic acid based methods detect organism specific DNA or RNA sequences
extracted from the microorganism. Nucleic acid–based tests are qualitative, but quantification methods do exist for
limited pathogens and can be useful for diagnosis and monitoring of response to treatment. Monitoring of any
infection by Real Time PCR [RT-PCR] assay has high end clinical value and utility in pace with critical care. It
detects/quantifies any infectious agent in any type of appropriate sample with high specificity and sensitivity. In
comparison to conventional cultures and serological detection assays real-time PCR assay has admirable
turnaround times. As this technique does not require post PCR processing, chances of false positivity is very
uncommon as compared to conventional PCR.
Some of the advantages of molecular detection by Real Time PCR are:
Wide range of pathogen detection
High sensitivity & specificity
High end clinical value and utility
Viral load monitoring
Low turnaround time compared to conventional methods
Testing of wide range specimen types
Sandor offers the following tests by Real time PCR:
Hepatitis B virus [HBV] detection, viral load and genotyping
Hepatitis C [HCV] detection, viral load and genotyping
Human Immuno deficiency virus [HIV-1] – detection and viral load
Herpes simples virus 1 &2 – detection
Cytomegalovirus[CMV]- viral load
Epstein-Barr virus[EBV]- viral load
Parvo virus B19- viral load
BK virus- viral load
JC virus - viral load
Human adenovirus- viral load
M. tuberculosis complex and non tuberculosis mycobacterium-detection
Catch Us At
1st International conference on Pediatric Rare Disease on 27th - 28th November 2015 at BM Birla Science &
Technology Centre, Statue Circle, Jaipur (www.ncpcc2015.com)
Feedback
We would like to hear from our Customers. We invite you to share your questions and comments with us. This can
be regarding existing tests, new tests that you might be interested in, the way we report results, other services that
we can provide, etc. Feel free to send your comments to us on promotions@sandor.co.in

Recommandé

Managing Abnormal LFTs par
Managing Abnormal LFTsManaging Abnormal LFTs
Managing Abnormal LFTsSt Mark's Academic Institute
1K vues27 diapositives
Autoimmune liver diseases par
Autoimmune liver diseasesAutoimmune liver diseases
Autoimmune liver diseasesElmuhtady Said FRCP FEBGH
1.3K vues30 diapositives
Auto immune hepatitis (Case + Theory) par
Auto immune hepatitis (Case + Theory)Auto immune hepatitis (Case + Theory)
Auto immune hepatitis (Case + Theory)MohammaD TanweeR
335 vues18 diapositives
Autoimmune hepatitis par
Autoimmune hepatitisAutoimmune hepatitis
Autoimmune hepatitisRintu Sharma
15.2K vues60 diapositives
Autoimmune hepatitis better understanding (2) par
Autoimmune hepatitis better understanding (2)Autoimmune hepatitis better understanding (2)
Autoimmune hepatitis better understanding (2)Mohit Aggarwal
4.1K vues50 diapositives
Ai hepatitis dr rintu par
Ai hepatitis dr rintuAi hepatitis dr rintu
Ai hepatitis dr rintuMohit Aggarwal
500 vues51 diapositives

Contenu connexe

Tendances

Future Developments in adult Intestinal Failure par
Future Developments in adult Intestinal FailureFuture Developments in adult Intestinal Failure
Future Developments in adult Intestinal FailureSt Mark's Academic Institute
897 vues32 diapositives
NAFLD, NASH par
NAFLD, NASHNAFLD, NASH
NAFLD, NASHShatdal Chaudhary
23K vues42 diapositives
Non Invasive Biomarkers in NASH (non-alcoholic steatohepatitis) Webinar Slides par
Non Invasive Biomarkers in NASH (non-alcoholic steatohepatitis) Webinar SlidesNon Invasive Biomarkers in NASH (non-alcoholic steatohepatitis) Webinar Slides
Non Invasive Biomarkers in NASH (non-alcoholic steatohepatitis) Webinar SlidesCovance
3.3K vues37 diapositives
Autoimmune Hepatitis par
Autoimmune HepatitisAutoimmune Hepatitis
Autoimmune HepatitisElmuhtady Said FRCP FEBGH
7.4K vues28 diapositives
NAFLD par
NAFLDNAFLD
NAFLDkatejohnpunag
13.3K vues39 diapositives
Non alcoholic fatty liver disease(NAFLD) par
Non alcoholic fatty liver disease(NAFLD)Non alcoholic fatty liver disease(NAFLD)
Non alcoholic fatty liver disease(NAFLD)Bhavin Mandowara
12.8K vues52 diapositives

Tendances(20)

Non Invasive Biomarkers in NASH (non-alcoholic steatohepatitis) Webinar Slides par Covance
Non Invasive Biomarkers in NASH (non-alcoholic steatohepatitis) Webinar SlidesNon Invasive Biomarkers in NASH (non-alcoholic steatohepatitis) Webinar Slides
Non Invasive Biomarkers in NASH (non-alcoholic steatohepatitis) Webinar Slides
Covance3.3K vues
Non alcoholic fatty liver disease(NAFLD) par Bhavin Mandowara
Non alcoholic fatty liver disease(NAFLD)Non alcoholic fatty liver disease(NAFLD)
Non alcoholic fatty liver disease(NAFLD)
Bhavin Mandowara12.8K vues
Autoimmune liver disease laboratory diagnosis par Dr. Rajesh Bendre
Autoimmune liver disease laboratory diagnosisAutoimmune liver disease laboratory diagnosis
Autoimmune liver disease laboratory diagnosis
Kw - Cases - Aih Pbc Psc par Neil Theise
Kw - Cases - Aih Pbc PscKw - Cases - Aih Pbc Psc
Kw - Cases - Aih Pbc Psc
Neil Theise771 vues
Nonalcoholic fatty liver disease in children and adolescents par joannayeh
Nonalcoholic fatty liver disease in children and adolescentsNonalcoholic fatty liver disease in children and adolescents
Nonalcoholic fatty liver disease in children and adolescents
joannayeh2.4K vues
Non alcoholic fatty liver disease par akifab93
Non alcoholic fatty liver diseaseNon alcoholic fatty liver disease
Non alcoholic fatty liver disease
akifab932.7K vues
Case presentation on pancreatitis par SaiSwapna3
Case presentation on pancreatitisCase presentation on pancreatitis
Case presentation on pancreatitis
SaiSwapna35.9K vues
Non alcoholic steatohepatitis copy par Keshri Yadav
Non alcoholic steatohepatitis   copyNon alcoholic steatohepatitis   copy
Non alcoholic steatohepatitis copy
Keshri Yadav4.4K vues
GIT J Club: NAFLD. par Shaikhani.
GIT J Club: NAFLD.GIT J Club: NAFLD.
GIT J Club: NAFLD.
Shaikhani.1.3K vues
Autoimmune hepatitis rajesh par Mohit Aggarwal
Autoimmune hepatitis rajeshAutoimmune hepatitis rajesh
Autoimmune hepatitis rajesh
Mohit Aggarwal13.3K vues
Nonalcoholic Steatohepatitis (NASH) Review par mfabzak
Nonalcoholic Steatohepatitis (NASH) ReviewNonalcoholic Steatohepatitis (NASH) Review
Nonalcoholic Steatohepatitis (NASH) Review
mfabzak1.1K vues
Fatty liver disease with Diabetes Mellitus [BANGLADESH] par drsamianik
Fatty liver disease with Diabetes Mellitus [BANGLADESH]Fatty liver disease with Diabetes Mellitus [BANGLADESH]
Fatty liver disease with Diabetes Mellitus [BANGLADESH]
drsamianik2.3K vues

En vedette

"Проблемы в IoT и их решение.", Артем Сорокин, DataArt par
"Проблемы в IoT и их решение.", Артем Сорокин, DataArt"Проблемы в IoT и их решение.", Артем Сорокин, DataArt
"Проблемы в IoT и их решение.", Артем Сорокин, DataArtDataArt
417 vues28 diapositives
Historia de la computacion par
Historia de la computacionHistoria de la computacion
Historia de la computacionjheromcm
126 vues6 diapositives
Reducing dependency on heating subsidies par
Reducing dependency on heating subsidiesReducing dependency on heating subsidies
Reducing dependency on heating subsidiesAnamaria Răvar
174 vues3 diapositives
우리 아이가 마음껏 뛰어 놀면서 집중력을 강화할 수 있는 스마트 토이가 등 장했어요! par
우리 아이가 마음껏 뛰어 놀면서 집중력을 강화할 수 있는 스마트 토이가 등 장했어요!우리 아이가 마음껏 뛰어 놀면서 집중력을 강화할 수 있는 스마트 토이가 등 장했어요!
우리 아이가 마음껏 뛰어 놀면서 집중력을 강화할 수 있는 스마트 토이가 등 장했어요!Billy Choi
953 vues10 diapositives
Apresentação Bacia Rio Doce par
Apresentação Bacia Rio Doce Apresentação Bacia Rio Doce
Apresentação Bacia Rio Doce CBH Rio das Velhas
294 vues91 diapositives
Infographic: Superalimente pentru super oameni par
Infographic: Superalimente pentru super oameniInfographic: Superalimente pentru super oameni
Infographic: Superalimente pentru super oameniCiprian Roman
140 vues1 diapositive

En vedette(14)

"Проблемы в IoT и их решение.", Артем Сорокин, DataArt par DataArt
"Проблемы в IoT и их решение.", Артем Сорокин, DataArt"Проблемы в IoT и их решение.", Артем Сорокин, DataArt
"Проблемы в IoT и их решение.", Артем Сорокин, DataArt
DataArt417 vues
Historia de la computacion par jheromcm
Historia de la computacionHistoria de la computacion
Historia de la computacion
jheromcm126 vues
Reducing dependency on heating subsidies par Anamaria Răvar
Reducing dependency on heating subsidiesReducing dependency on heating subsidies
Reducing dependency on heating subsidies
Anamaria Răvar174 vues
우리 아이가 마음껏 뛰어 놀면서 집중력을 강화할 수 있는 스마트 토이가 등 장했어요! par Billy Choi
우리 아이가 마음껏 뛰어 놀면서 집중력을 강화할 수 있는 스마트 토이가 등 장했어요!우리 아이가 마음껏 뛰어 놀면서 집중력을 강화할 수 있는 스마트 토이가 등 장했어요!
우리 아이가 마음껏 뛰어 놀면서 집중력을 강화할 수 있는 스마트 토이가 등 장했어요!
Billy Choi953 vues
Infographic: Superalimente pentru super oameni par Ciprian Roman
Infographic: Superalimente pentru super oameniInfographic: Superalimente pentru super oameni
Infographic: Superalimente pentru super oameni
Ciprian Roman140 vues
REGULATED INSTRUCTIONS TO EFFECT CHANGES IN PROPERTY DOCUMENTS par Advocate Selvakumar
REGULATED INSTRUCTIONS TO EFFECT CHANGES IN PROPERTY DOCUMENTSREGULATED INSTRUCTIONS TO EFFECT CHANGES IN PROPERTY DOCUMENTS
REGULATED INSTRUCTIONS TO EFFECT CHANGES IN PROPERTY DOCUMENTS
Player's Belief Estimation for Super Human Sports par Kiminao Kogiso
Player's Belief Estimation for Super Human SportsPlayer's Belief Estimation for Super Human Sports
Player's Belief Estimation for Super Human Sports
Kiminao Kogiso631 vues
Anaerobic Digestion – Overview of Current Planning Practices and Policy in th... par Sophie Drew
Anaerobic Digestion – Overview of Current Planning Practices and Policy in th...Anaerobic Digestion – Overview of Current Planning Practices and Policy in th...
Anaerobic Digestion – Overview of Current Planning Practices and Policy in th...
Sophie Drew454 vues
Aπό τη ρώμη στη νέα ρώμη par 4gymsch
Aπό τη ρώμη στη νέα ρώμηAπό τη ρώμη στη νέα ρώμη
Aπό τη ρώμη στη νέα ρώμη
4gymsch200 vues

Similaire à Newsletter Issue 1

Fulminant hepatic failure (fhf) par
Fulminant hepatic failure (fhf)Fulminant hepatic failure (fhf)
Fulminant hepatic failure (fhf)Reyad Al_Faky
22.4K vues108 diapositives
LFT par
LFTLFT
LFTAjay Agade
2.8K vues9 diapositives
Liver Function Tests and their Interpretation.pdf par
Liver Function Tests and their Interpretation.pdfLiver Function Tests and their Interpretation.pdf
Liver Function Tests and their Interpretation.pdfssuser6dbad41
35 vues9 diapositives
Multifactorial Conditions of Failure to Thrive par
Multifactorial Conditions of Failure to ThriveMultifactorial Conditions of Failure to Thrive
Multifactorial Conditions of Failure to ThriveRenée Morrison, MSPH RD
937 vues51 diapositives
paper_9_9748_307.pdf par
paper_9_9748_307.pdfpaper_9_9748_307.pdf
paper_9_9748_307.pdfnorlandoriiz
4 vues13 diapositives
systemic lupus erythematosus par
systemic lupus  erythematosussystemic lupus  erythematosus
systemic lupus erythematosusKirsha K S
21.3K vues42 diapositives

Similaire à Newsletter Issue 1(20)

Fulminant hepatic failure (fhf) par Reyad Al_Faky
Fulminant hepatic failure (fhf)Fulminant hepatic failure (fhf)
Fulminant hepatic failure (fhf)
Reyad Al_Faky22.4K vues
Liver Function Tests and their Interpretation.pdf par ssuser6dbad41
Liver Function Tests and their Interpretation.pdfLiver Function Tests and their Interpretation.pdf
Liver Function Tests and their Interpretation.pdf
ssuser6dbad4135 vues
systemic lupus erythematosus par Kirsha K S
systemic lupus  erythematosussystemic lupus  erythematosus
systemic lupus erythematosus
Kirsha K S21.3K vues
ACUTE LIVER FAILURE - APPROACH AND MANAGEMENT par Nishant Yadav
ACUTE LIVER FAILURE - APPROACH AND MANAGEMENTACUTE LIVER FAILURE - APPROACH AND MANAGEMENT
ACUTE LIVER FAILURE - APPROACH AND MANAGEMENT
Nishant Yadav5.7K vues
2014 09-10 ACI biomarker utilisation & commercialisation, London par Alain van Gool
2014 09-10 ACI biomarker utilisation & commercialisation, London2014 09-10 ACI biomarker utilisation & commercialisation, London
2014 09-10 ACI biomarker utilisation & commercialisation, London
Alain van Gool1.2K vues
Protocol based approach to metabolic liver disease seema alam par Sanjeev Kumar
Protocol based approach to metabolic liver disease  seema alamProtocol based approach to metabolic liver disease  seema alam
Protocol based approach to metabolic liver disease seema alam
Sanjeev Kumar3.8K vues
neonatal cholestasis by dinesh viruvanti par Dinesh Viruvanti
neonatal cholestasis by dinesh viruvantineonatal cholestasis by dinesh viruvanti
neonatal cholestasis by dinesh viruvanti
Dinesh Viruvanti2.2K vues

Dernier

Low Vision Managment, Age Related Macular Degeneration ARMD par
Low Vision Managment, Age Related Macular Degeneration ARMDLow Vision Managment, Age Related Macular Degeneration ARMD
Low Vision Managment, Age Related Macular Degeneration ARMDmahendra singh
9 vues31 diapositives
GULLAIN BARRE SYNDROME.pptx par
GULLAIN BARRE SYNDROME.pptxGULLAIN BARRE SYNDROME.pptx
GULLAIN BARRE SYNDROME.pptxMeenakshiGursamy
9 vues11 diapositives
patient consuling. par
patient consuling.patient consuling.
patient consuling.pratikshagharat
33 vues14 diapositives
SMART RADIOLOGY : AI INNOVATIONS par
SMART RADIOLOGY  : AI INNOVATIONS SMART RADIOLOGY  : AI INNOVATIONS
SMART RADIOLOGY : AI INNOVATIONS vaarunimi
42 vues25 diapositives
Community-Engagement_SNEHA-Dissemination-15th-Nov.-2019.pdf par
Community-Engagement_SNEHA-Dissemination-15th-Nov.-2019.pdfCommunity-Engagement_SNEHA-Dissemination-15th-Nov.-2019.pdf
Community-Engagement_SNEHA-Dissemination-15th-Nov.-2019.pdfmanali9054
26 vues3 diapositives
Working-across-sectors_fulldraftreport_Aug-2019.pdf par
Working-across-sectors_fulldraftreport_Aug-2019.pdfWorking-across-sectors_fulldraftreport_Aug-2019.pdf
Working-across-sectors_fulldraftreport_Aug-2019.pdfmanali9054
26 vues37 diapositives

Dernier(20)

Low Vision Managment, Age Related Macular Degeneration ARMD par mahendra singh
Low Vision Managment, Age Related Macular Degeneration ARMDLow Vision Managment, Age Related Macular Degeneration ARMD
Low Vision Managment, Age Related Macular Degeneration ARMD
SMART RADIOLOGY : AI INNOVATIONS par vaarunimi
SMART RADIOLOGY  : AI INNOVATIONS SMART RADIOLOGY  : AI INNOVATIONS
SMART RADIOLOGY : AI INNOVATIONS
vaarunimi42 vues
Community-Engagement_SNEHA-Dissemination-15th-Nov.-2019.pdf par manali9054
Community-Engagement_SNEHA-Dissemination-15th-Nov.-2019.pdfCommunity-Engagement_SNEHA-Dissemination-15th-Nov.-2019.pdf
Community-Engagement_SNEHA-Dissemination-15th-Nov.-2019.pdf
manali905426 vues
Working-across-sectors_fulldraftreport_Aug-2019.pdf par manali9054
Working-across-sectors_fulldraftreport_Aug-2019.pdfWorking-across-sectors_fulldraftreport_Aug-2019.pdf
Working-across-sectors_fulldraftreport_Aug-2019.pdf
manali905426 vues
Oral presentaion slides.pptx par anwahiamna
Oral presentaion slides.pptxOral presentaion slides.pptx
Oral presentaion slides.pptx
anwahiamna5 vues
Whole Egg Powder Manufacturing Plant Project Report 2024 par AlinaEllis1
Whole Egg Powder Manufacturing Plant Project Report 2024Whole Egg Powder Manufacturing Plant Project Report 2024
Whole Egg Powder Manufacturing Plant Project Report 2024
AlinaEllis111 vues
Evovitality Revolutionizing Wellness for a Better Tomorrow.pdf par muhammadtahirbhutto9
Evovitality Revolutionizing Wellness for a Better Tomorrow.pdfEvovitality Revolutionizing Wellness for a Better Tomorrow.pdf
Evovitality Revolutionizing Wellness for a Better Tomorrow.pdf
FROSTBITE par A Y
FROSTBITE FROSTBITE
FROSTBITE
A Y6 vues
2024 Medicare Physician Fee Schedule (MPFS) Final Rule Updates par Health Catalyst
2024 Medicare Physician Fee Schedule (MPFS) Final Rule Updates2024 Medicare Physician Fee Schedule (MPFS) Final Rule Updates
2024 Medicare Physician Fee Schedule (MPFS) Final Rule Updates
Health Catalyst151 vues
Paper Napkin Manufacturing Plant Project Report 2024 par AlinaEllis1
Paper Napkin Manufacturing Plant Project Report 2024Paper Napkin Manufacturing Plant Project Report 2024
Paper Napkin Manufacturing Plant Project Report 2024
AlinaEllis15 vues
Communication and NPR Presentation.pptx par Winnie
Communication and NPR Presentation.pptxCommunication and NPR Presentation.pptx
Communication and NPR Presentation.pptx
Winnie 10 vues
Rebuild Your Lifestyle with our Expert Health Fitness Tips par Google
Rebuild Your Lifestyle with our Expert Health Fitness TipsRebuild Your Lifestyle with our Expert Health Fitness Tips
Rebuild Your Lifestyle with our Expert Health Fitness Tips
Google5 vues
New Microsoft Word Document (2).docx par ElyaGhiasyan
New Microsoft Word Document (2).docxNew Microsoft Word Document (2).docx
New Microsoft Word Document (2).docx
ElyaGhiasyan10 vues

Newsletter Issue 1

  • 1. Issue 1, December 2015 Sandor Lifesciences Pvt. Ltd. 8-2-326/5, Plot No. 1, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India CIN: U85110TG2004PTC043672 Page 1 New Tests Now Available 1. Newborn Screening 2. Vitamins 3. Lactate & Pyruvate 4. Pterins Tests Coming Soon 1. LSD’s screening 2. Non-invasive prenatal testing (NIPT) Dear Clinicians, We are happy to launch our first edition of quarterly newsletter bringing to your exotic clinical cases with unusual symptoms and/or diagnostic findings, or cases involving rare diseases. We will also share with you our recent achievements, the future roadmap and new test launches in the field of rare disorder diagnosis. We hope that you will find this information quite valuable as it may assist you to derive even better patient management. Thanks for reading! Team Sandor In This Issue 1. Wolman Disease 2. Lysinuric Protein Intolerance (LPI) 3. Molecular Diagnostics of Infectious Disease Consultant Geneticist & Lab Chief Dr. Jayanthi Undamatla jayanthi@sandor.co.in, +91 83310 11704 Consultant Biochemist Dr. Maheshwar Reddy mahesh@sandor.co.in, +91 83319 30016 Principal Scientist Flow Cytometry Dr. Nagesh Narayan Pandey nagesh@sandor.co.in, +91 83329 59992 Consultant Molecular Diagnostics Dr. Raghuram raghu@sandor.co.in, +91 94406 97547
  • 2. Issue 1, December 2015 Sandor Lifesciences Pvt. Ltd. 8-2-326/5, Plot No. 1, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India CIN: U85110TG2004PTC043672 Page 2 Case 1: Wolman disease (OMIM No: 278000) A two months male child with acid lipase enzyme activity deficiency Clinical presentation: The child presented with clinical suspicion of Wolman disease with hepatosplenomegaly, calcified adrenal glands, diarrhea and failure to thrive. Laboratory work up: Acid lipase enzyme activity was found to be deficient (~ 2.1% of mean normal) in leukocytes. In view of the age of onset and clinical presentation the diagnosis was consistent with Wolman disease. About the disorder: Both Wolman disease and Cholesteryl ester storage disease are rare autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase, the differentiating factor being the age of onset and clinical presentation. Wolman disease is the early onset form and develops during the first few weeks or month of life and presents with hepatomegaly, liver disease, adrenal gland calcification, vomiting, diarrhea, and failure to thrive. The late onset form which is known as Cholesteryl ester storage disease (CESD) typically presents later in childhood or even adulthood and presents with hepatosplenomegaly, coronary artery disease, stroke, altered liver function, jaundice, steatosis, fibrosis, cirrhosis and related complications of esophageal varices, and/or liver failure, anemia and/or thrombocytopenia. Residual enzyme activity of ≤5% of mean normal is obtained in Wolman disease and 2% - 11% of mean normal is observed in Cholesterol ester storage disease (CESD). Prevalence: Wolman disease is estimated to occur in 1 in 100,000 newborns and CESD is 1 in 1, 30,000 live births. Differentials: Owing to its similarity with other cardiovascular, liver and metabolic diseases, the differential diagnosis of these disorders can be challenging. The differential diagnosis includes: Niemann-Pick disease, Types A/B Gaucher disease Familial hypercholesterolemia Chanarin dorfman syndrome Copyrights: http://ommbid.mhmedical.com/data/Books/ommbid/ch142fg2.jpg http://pmj.bmj.com/content/78/923/567/F2.large.jpg
  • 3. Issue 1, December 2015 Sandor Lifesciences Pvt. Ltd. 8-2-326/5, Plot No. 1, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India CIN: U85110TG2004PTC043672 Page 3 Case 2: Lysinuric Protein Intolerance (LPI) (OMIM No: 222700) A two years eleven months male child born from a consanguineous marriage presented with hyper ammonia Clinical presentation: The child presented with an eight month history of daily episodic irritability lasting for up to twelve hours associated slow congitive regression. The child was being treated for epilepsy with multiple anticonvulsants without any improvement. His EEG was normal and MRI had shown symmetrical periventricular T2 hyperintensities. On clinical Examination he was pale, ataxic and had mild hepatosplenomegaly. Prior work up: His serum Ammonia was significantly raised at 840 micromol/l as were plasma ferritin with mild derangment of liver function. Clinically urea cycle disorder was suspected. Diagnostic workup: The patient was referred for metabolic work up including urine organic acid analysis, urine & plasma amino acid analysis. Urine organic acid analysis revealed a 689-fold elevation of orotic acid and 6-fold elevation of uracil. Plasma amino acid analysis revealed an elevation of alanine, low level of lysine, absence of ornithine but arginine was within normal limits. Urine amino acid analysis revealed increase in multiple amino acids including glutamic acid, glutamine, α-amino adipic acid, citrulline, amino butyric acid, cystine, methionine, phenylalanine, lysine, and arginine, but ornithine was within normal limits. Treatment: The child showed dramatic improvement in his symptomatology after starting anitscavanging therapy (Sodium benzoate and Citrulline) and protein restricted diet. About the disorder: Lysinuric protein intolerance is an autosomal recessive disorder caused by defective cationic amino acid (CAA) transport at the basolateral membrane of epithelial cells in kidney and intestine. Clinical symptoms are presented at infancy after weaning from being breast-fed and include hepatomegaly, pancreatitis, splenomegaly, nausea, vomiting diarrhea, and aversion to protein rich food, impaired intestinal absorption of cationic amino acids, chronic renal disease, and impaired renal absorption of CAA, mental retardation, postprandial hyperammonemia, anemia, leucopenia and thrombocytopenia. The patients look as if they have protein deficiency or malnutrition, loose skin, hypotonia, muscle weakness, interstitial changes on chest x-ray, respiratory insufficiency and pulmonary hemorrhage. The phenotypic variability of lysinuric protein intolerance (LPI) has resulted in various differentials. Differentials Urea Cycle disorders Malnutrition/ malabsorptive diseases Lysosomal storage diseases (LSDs) Hemophagocytic lymphohistiocytosis/macrophagic activation syndrome Autoimmune disorders
  • 4. Issue 1, December 2015 Sandor Lifesciences Pvt. Ltd. 8-2-326/5, Plot No. 1, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India CIN: U85110TG2004PTC043672 Page 4 Urine Amino acid Chromatogram 25.0 50.0 75.0 100.0 125.0 min 0 100 200 300 400 500 600 700 800 900 1000 mV Detector A:Ex:350nm,Em:450nm P-Ser Tau Asp Thr Ser Asn Glu aAAA Gly Ala Cit aABA Val Cys Met Ile Leu Tyr Phe b-AlabAIBA GABA Trp His1-Me-His 3-Me-His Car Ans Orn Lys NH3+Ethanolamine Arg Urine Organic acid chromatogram 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 0.00 0.25 0.50 0.75 1.00 1.25 1.50 (x10,000,000) TIC Oxalicacid-2TMS Malonicacid-2TMS Succinicacid-2TMS Uracil-2TMS Tropicacid(IS) 2-Ketoglutaricacid-oxime-3TMS Oroticacid-3TMS Hippuricacid-TMS Citricacid-4TMS PalmiticacidTMS Margaricacid-TMS(IS) Tetracosane(IS) Plasma Amino acid Chromatogram 25.0 50.0 75.0 100.0 125.0 min 0 100 200 300 400 500 600 700 800 900 1000 mV Detector A:Ex:350nm,Em:450nm P-Ser Tau Asp Thr Ser Asn Glu Gly Ala Cit aABA Val Cys Met Ile Leu Tyr Phe b-AlabAIBA Trp His1-Me-His Lys NH3+Ethanolamine Arg
  • 5. Issue 1, December 2015 Sandor Lifesciences Pvt. Ltd. 8-2-326/5, Plot No. 1, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India CIN: U85110TG2004PTC043672 Page 5 Molecular Diagnostics of Infectious Diseases (New Tests) At Sandor, our goal is to assist clinicians to make quicker decisions in the prognosis and management of different infections. Molecular identification in clinical settings is a faster method allowing clinicians to avoid prolonged management based on empiric medication and to implement specific therapy. Molecular diagnostics based on Nucleic acid based methods detect organism specific DNA or RNA sequences extracted from the microorganism. Nucleic acid–based tests are qualitative, but quantification methods do exist for limited pathogens and can be useful for diagnosis and monitoring of response to treatment. Monitoring of any infection by Real Time PCR [RT-PCR] assay has high end clinical value and utility in pace with critical care. It detects/quantifies any infectious agent in any type of appropriate sample with high specificity and sensitivity. In comparison to conventional cultures and serological detection assays real-time PCR assay has admirable turnaround times. As this technique does not require post PCR processing, chances of false positivity is very uncommon as compared to conventional PCR. Some of the advantages of molecular detection by Real Time PCR are: Wide range of pathogen detection High sensitivity & specificity High end clinical value and utility Viral load monitoring Low turnaround time compared to conventional methods Testing of wide range specimen types Sandor offers the following tests by Real time PCR: Hepatitis B virus [HBV] detection, viral load and genotyping Hepatitis C [HCV] detection, viral load and genotyping Human Immuno deficiency virus [HIV-1] – detection and viral load Herpes simples virus 1 &2 – detection Cytomegalovirus[CMV]- viral load Epstein-Barr virus[EBV]- viral load Parvo virus B19- viral load BK virus- viral load JC virus - viral load Human adenovirus- viral load M. tuberculosis complex and non tuberculosis mycobacterium-detection Catch Us At 1st International conference on Pediatric Rare Disease on 27th - 28th November 2015 at BM Birla Science & Technology Centre, Statue Circle, Jaipur (www.ncpcc2015.com) Feedback We would like to hear from our Customers. We invite you to share your questions and comments with us. This can be regarding existing tests, new tests that you might be interested in, the way we report results, other services that we can provide, etc. Feel free to send your comments to us on promotions@sandor.co.in